BAT6026 not checked
Bio-Thera Solutions · anti-OX40 monoclonal antibody
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)”In the company’s words, NCT06094179 on ClinicalTrials.gov
- Tested for
- Dermatitis, Atopic
- Main trialPhase 1/2
- “This is a Phase IB/IIA clinical study of BAT6026 in patients with AD. The subjects were adults with moderate to severe atopic dermatitis (AD) whose disease was not adequately controlled by prior topical medications or for which topical medications were not appropriate. The first phase was the phase IB study, which was double-blind controlled by placebo in the group and consisted of 3 dose groups. After completing the dose escalation study, the phase IIA study was entered. The Phase IIA study was a randomized, double-blind, controlled, multicentering clinical trial with different dose groups…”In the company’s words, NCT06094179 on ClinicalTrials.gov
- Other names
- anti-OX40 monoclonal antibody
Other drugs for Dermatitis, Atopic
Coming up1
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 31 Dec 2026 | Evaluate the Safety, Tolerability of BAT6026 | |
| Phase 1Terminated | 23 Mar 2023 | Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients | |
| Phase 1Completed | 14 Nov 2023 | Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026